COGT - Cogent stock rises on promising interim data from mid-stage study of rare blood disorder drug

Cogent Biosciences (NASDAQ:COGT) stock rose ~5% premarket June 10 after the company reported initial data from an ongoing phase 2 trial of bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). Systemic Mastocytosis is a rare disorder in which a type of white blood cell called mast cell accumulate in internal tissues and organs such as the liver, spleen and bone marrow. The study, dubbed APEX, is a two part phase 2 trial. The company reported data from 11 patients in part 1 who were treated with one of four dose levels (50 mg BID, 100 mg BID, 200 mg BID or 400 mg QD). The company said all 11 patients achieved ?50% reduction in serum tryptase levels. About 89% median reduction in serum tryptase; 6 out of 11 patients achieved reduction to <20 ng/mL. Cogent added that 8/8 patients achieved ?50% reduction in bone marrow mast cells; 6/8 patients achieved complete clearance of bone

For further details see:

Cogent stock rises on promising interim data from mid-stage study of rare blood disorder drug